In The Spotlight

AtriCure is a medical device company offering surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management.

Demodex blepharitis, caused by infestation of Demodex mites, is characterized by collarettes, leading to eyelid itching/burning, blurred vision and negative impact on daily life. There are currently no FDA-approved therapies for Demodex blepharitis. Every year, about 2.1 million cases of blepharitis are reported in the U.S.

89bio Inc. (ETNB) has a key clinical trial catalyst to watch in the coming months. The company's lead drug candidate is Pegozafermin, formerly BIO89-100, a long-acting engineered glycopegylated recombinant human fibroblast growth factor 21 (FGF21) analogue, being developed for severe hypertriglyceridemia and non-alcoholic steatohepatitis.

Shares of AdaptHealth Corp. (AHCO) have lost nearly 29% of their value so far this year and trade around $17.